New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
21:06 EDTKPTIKaryopharm presents data for Selinexor at ASH
Karyopharm Therapeutics announced the oral presentation of clinical data from an ongoing Phase 1 clinical trial of its lead oral SINE compound, Selinexor, KPT-330, in patients with relapsed and/or refractory non-Hodgkin lymphoma, NHL, and chronic lymphocytic leukemia, CLL, at the 2013 American Society of Hematology, ASH, Annual Meeting and Exposition being held December 7-10 in New Orleans.The data indicate that, as of December 4, first-in-class oral Selinexor showed preliminary evidence of anti-cancer activity as a single agent in the majority of heavily pretreated relapsed and/or refractory NHL and CLL patients in the study cohort with progressive disease on study entry. In these NHL and CLL patients, Selinexor induced low levels of severe adverse events, and several of these patients have remained on study with Selinexor as their only anti-cancer treatment for more than 6-12 months.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
08:53 EDTKPTIConcerns over Karyopharm overdone, says Wedbush
After eight AML patients taking Karyopharm's Sellinexor developed Sepisis versus two in the control arm, Wedbush quotes a doctor as saying that differences in patients' characteristics between the two arms may have contributed to the high rate of Sepsis in those taking Sellinexor,. Wedbush believes that a study of the 60 mg version of the drug, due out in 4Q16, will show that it improves survival and has an acceptable safety profile. Wedbush increased its discount rate on AML to 45% from 30% to account for higher risk from a reduced dose and cut its price target on the name to $39 from $50, mostly due to the postponement of clinical trial results. However, the firm keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use